---
figid: PMC10838672__MCO2-5-e474-g001
figtitle: PI3K/AKT/mTOR signaling pathway and targeted inhibitors
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10838672
filename: MCO2-5-e474-g001.jpg
figlink: /pmc/articles/PMC10838672/figure/F3
number: F3
caption: PI3K/AKT/mTOR signaling pathway and targeted inhibitors. Dysregulation of
  PI3K/AKT/mTOR signaling enhances the Warburg effect in tumors, promotes cell proliferation
  and metastasis in HCC. In addition, we describe the latest clinical trials of inhibitors
  targeting the PI3K/AKT/mTOR pathway. 4EBP1, eukaryotic translation initiation factor
  4E‐binding protein 1; BAD, bcl‐2 agonist of cell death; ERBB2, human epidermal growth
  factor receptor‐2; FOXO1, Forkhead box O1; GSK‐3β, glycogen synthetase kinase‐3beta;
  MET, mesenchymal epithelial transfer factor; mTOR, mammalian target of rapamycin;
  PIP2, phosphatidylinositol‐4,5‐diphosphate; PIP3, phosphatidylinositol‐3,4,5‐diphosphate;
  PTEN, phosphatase and tensin homolog; PI3K, phosphoinositide 3‐kinase; RET, rearranged
  during transfection; S6K, S6 kinase; SREBP, sterol regulatory element binding protein;
  SRPK2, arginine protein kinase 2; TSC, tuberous sclerosis complex
papertitle: 'Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy'
reftext: Xiaoting Luo, et al. MedComm (2020). 2024 Feb;5(2).
year: '2024'
doi: 10.1002/mco2.474
journal_title: MedComm
journal_nlm_ta: MedComm (2020)
publisher_name: John Wiley and Sons Inc.
keywords: hepatocellular carcinoma | immunotherapy | signaling pathways | targeted
  therapy
automl_pathway: 0.9475084
figid_alias: PMC10838672__F3
figtype: Figure
redirect_from: /figures/PMC10838672__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10838672__MCO2-5-e474-g001.html
  '@type': Dataset
  description: PI3K/AKT/mTOR signaling pathway and targeted inhibitors. Dysregulation
    of PI3K/AKT/mTOR signaling enhances the Warburg effect in tumors, promotes cell
    proliferation and metastasis in HCC. In addition, we describe the latest clinical
    trials of inhibitors targeting the PI3K/AKT/mTOR pathway. 4EBP1, eukaryotic translation
    initiation factor 4E‐binding protein 1; BAD, bcl‐2 agonist of cell death; ERBB2,
    human epidermal growth factor receptor‐2; FOXO1, Forkhead box O1; GSK‐3β, glycogen
    synthetase kinase‐3beta; MET, mesenchymal epithelial transfer factor; mTOR, mammalian
    target of rapamycin; PIP2, phosphatidylinositol‐4,5‐diphosphate; PIP3, phosphatidylinositol‐3,4,5‐diphosphate;
    PTEN, phosphatase and tensin homolog; PI3K, phosphoinositide 3‐kinase; RET, rearranged
    during transfection; S6K, S6 kinase; SREBP, sterol regulatory element binding
    protein; SRPK2, arginine protein kinase 2; TSC, tuberous sclerosis complex
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ERBB2
  - EGFR
  - KDR
  - FLT1
  - FLT4
  - RET
  - PDK1
  - PDPK1
  - AKT1
  - AKT2
  - AKT3
  - PTEN
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - CUX1
  - SART3
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - TSC2
  - RPTOR
  - TSC1
  - CCL26
  - GSK3B
  - EIF4EBP1
  - RPS6KB1
  - BAD
  - SRPK2
  - FOXO1
  - CCND1
  - HIF1A
  - MYC
  - MET
  - Rapamycin
  - Copanlisib
  - Nucleus
---
